Short-Term Debt to Equity Ratio: Minerva Neurosciences (NERV)
The price history on the Minerva Neurosciences (NERV) chart on the GURU.Markets platform demonstrates the dynamics of an asset valued at 0.00. The brand maintains high authority among physicians due to its success in treating severe psychoses. However, the business faces intense pressure from industry behemoths and high regulatory risks. Management is currently implementing a strategic pivot, correcting research errors to secure FDA drug approval.
Metric breakdowns and analytics for minervaneurosciences.com (NERV)
- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
- issuer book value statistics:
- company liabilities and liquidity data:
Debt to Equity Minerva Neurosciences|NERV - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Minerva Neurosciences, Inc.|NERV - Company Total Debt Obligations|Debt to Book Capitalization Ratio Minerva Neurosciences Inc|NERV - Company Long-Term Indebtedness|Company Short-Term Debts Minerva Neurosciences|Quick Liquidity minervaneurosciences.com
- company profitability and valuation multiples indicators:
Basic company analysis:NERV Minerva Neurosciences Corp
Minerva Neurosciences (NERV) is scaling its search for neuropsychiatric drugs through automated bioinformatic protein analysis, which requires significant operating expenses. By analyzing changes in the ratio of short-term debt to equity, an investor assesses the volume of liabilities due within one year relative to equity, using this indicator to identify the risk of cash flow gaps or costs associated with upgrading laboratory equipment.
Who Minerva Neurosciences competes with
Short-Term Debt to Capital BIIB|NBIX - Current Liabilities to Capital|Regencell Bioscience - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital axsome.com AXSM|ACAD - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital XENE (Xenon Pharmaceuticals Inc.)|Viking Pharma (VKTX) - Short-Term Debt to Equity|Current Liabilities to Capital Supernus Corp (SUPN)|Short-Term Debt to Equity Catalyst Pharmaceuticals|Short-Term Debt to Equity Ratio denalitherapeutics.com (DNLI)|Short-Term Debt to Capital HRMY|Short-Term Debt to Capital Coefficient Biohaven Ltd|Short-Term Debt to Equity Amylyx AMLX|TRVI: Short-Term Debt to Capital Ratio|Praxis Precision Medicines - Short-Term Debt to Capital|Current Liabilities to Capital anavex.com|CeriBell (CBLL) - Short-Term Debt to Equity|Prothena Biosciences - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Ratio ALEC|Short-Term Debt to Equity ANNX|Short-Term Debt to Capital OMER|Short-Term Debt to Capital neurogene.com (NGNE)|AC Immune SA - Short-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital VYGR|NMRA - Short-Term Debt to Equity|SCLX (Scilex Holding Company, Inc.) - Short-Term Debt to Capital Ratio|TVGN: Short-Term Debt to Capital|Current Liabilities to Capital Alpha Cognition Inc. (ACOG)|Short-Term Debt to Equity Ratio CGTX|Short-Term Debt to Capital Inhibikase Therapeutics Inc|Short-Term Debt to Equity Cassava (SAVA)|ASRT (assertiotx.com) - Ratio of Short-Term Indebtedness to Capital|Short-Term Debt to Equity Coya Therapeutics COYA|VistaGen Therapeutics, Inc. (VTGN) - Current Liabilities to Capital|OVID - Short-Term Debt to Equity|Short-Term Debt to Capital Coefficient Acumen Pharmaceuticals Inc. ABOS|CRVO: Short-Term Debt to Capital|Short-Term Debt to Equity Ratio Alterity Therapeutics Limited|CLNN (Clene Inc) - Short-Term Debt to Capital|PepGen Corp (PEPG) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Capital JUNS|RLMD - Current Liabilities to Capital|Short-Term Debt to Equity Annovis Bio Corp ANVS|GRCE: Short-Term Debt to Capital Ratio|Firefly Neuroscience, Inc - Short-Term Debt to Capital|Klotho Neurosciences Inc (KLTO) - Short-Term Debt to Equity Ratio|NRSN: Short-Term Debt to Capital|Current Liabilities to Capital Reviva Pharmaceuticals Holdings Inc. (RVPH)|Short-Term Debt to Equity MetaVia Inc.|NeurAxis Inc (NRXS) - Short-Term Debt to Capital Coefficient|Short-Term Debt to Equity Helius Medical (HSDT)|passagebio.com - Short-Term Debt to Capital Ratio|Short-Term Debt to Capital NEUP (Neuphoria Therapeutics)|Athira Pharma Inc (ATHA) - Current Liabilities to Capital|ADXN - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ALZN (Alzamend Neuro, Inc.)|CYCN (cyclerion.com) - Short-Term Debt to Equity Ratio|PTIX (Protagenic Therapeutics, Inc.) - Short-Term Debt to Equity|Short-Term Debt to Equity Pasithea Therapeutics Corp|Short-Term Debt to Capital Ratio CRGT (Cortigent Medical)|Short-Term Debt to Capital ATXI|BCLI - Current Liabilities to Capital|Cara Therapeutics, Inc. - Short-Term Debt to Equity Ratio|Short-Term Debt to Capital chromocell.com CHRO|ELYM - Short-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital ITCI (Intra-Cellular Therapies)|Longboard Pharma (LBPH) - Short-Term Debt to Equity|Current Liabilities to Capital Marinus Pharma (MRNS)|Short-Term Debt to Equity NKGen Biotech, Inc.|Short-Term Debt to Equity Ratio neurobopharma.com (NRBO)|Short-Term Debt to Capital SAGE|Short-Term Debt to Capital Coefficient Synaptogenix Inc.|Short-Term Debt to Equity Trevena, Inc TRVN|VIGL: Short-Term Debt to Capital Ratio|Anew Medical, Inc. - Short-Term Debt to Capital|Current Liabilities to Capital cerevel.com